NCT07632001
Miro3D Wound Matrix for Treatment of Diabetic Foot Ulcers
Recruiting
NAAges 18+InterventionalTreatmentReprise Biomedical, Inc.
~180 participants
Updated 2026-06-08 on ClinicalTrials.gov
What's tested:Miro3D Wound MatrixStandard of Care
At a glance
Recruiting sites
6 of 14 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Proportion of Participants Achieving Complete Wound Closure of the Target Diabetic Foot Ulcer at 12 Weeks
Measured over Up to 12 weeks
+1 more outcome measured
Conditions
Where it's being run
14 sites across 8 statesFlorida4
Missouri3
Texas2
Arizona1
Massachusetts1
New York1
Ohio1
Oklahoma1
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
What this trial measures
- Proportion of Participants Achieving Complete Wound Closure of the Target Diabetic Foot Ulcer at 12 WeeksUp to 12 weeks
Complete wound closure is defined as full re-epithelialization of the target ulcer without drainage or need for dressing, with closure confirmed at a single healing confirmation visit conducted approximately two weeks after complete closure is initially documented.
- Mean Percentage Reduction in Target Ulcer Surface Area From Baseline to 12 WeeksBaseline through 12 weeks
Percentage area reduction (PAR) is defined as the percent change in surface area of the target ulcer from baseline, as measured by digital planimetry.